LicensingMiddle East
Arcera Life Sciences Secures Exclusive License from Innogen Pharmaceuticals to Advance Cardiometabolic Therapies Globally
Arcera Life Sciences and Innogen Pharmaceuticals have entered an exclusive licensing agreement to commercialize Efsubaglutide Alfa, a next-generation GLP-1 receptor agonist, in selected international markets. This collaboration combines Innogen’s metabolic disease expertise with Arcera’s regulatory and commercial capa…
Thursday, November 19, 2026